Literature DB >> 6576197

Peritoneal plasmacytomagenesis in mice: comparison of different pristane dose regimens.

M Potter, J S Wax.   

Abstract

Plasmacytomas were induced in inbred BALB/c pi mice by the ip injection of pristane with 4 different dose schedules. Three 0.5-ml doses (1.5 ml) given at 2-month intervals gave an average yield of 61% plasmacytomas in 6 experimental groups with a range from 51 to 71%; a single 1-ml dose gave an average yield of 42% plasmacytomas in 5 experimental groups with a range from 37 to 45%; and a single 0.5-ml dose gave an average of 22% from 3 experiments involving young mice with a range from 14 to 26%. Two 0.5-ml doses given at various intervals from 14 to 300 days gave yields of plasmacytomas that usually but not always were greater than that obtained with a single 0.5-ml dose of pristane. When the second injection of pristane was delayed as long as 180 days, a strong additive effect over that observed with 0.5 ml alone was obtained. The plasmacytomas developed in mice given the second dose 180 days after the first, with virtually the same latent period as observed with a single 1-ml dose. No plasmacytomas were found in 200 BALB/c pi mice inoculated with corn oil, aluminum hydroxide, or very small doses of pristane (i.e., 0.05 ml). The minimal latent period for plasmacytoma development is about 120 days. The median latent period ranged from 180 to 250 days in the groups of mice that received 3 0.5-ml injections of pristane. In a single experiment pristane freed of UV-absorbing materials was as potent as commercial grade pristane in inducing plasmacytomas.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6576197

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  17 in total

1.  Assessment of all-trans retinoic acid (ATRA) efficacy as a single agent in primary lymphoid neoplasia.

Authors:  N Swaminathan; G Lopez-Berestein; S Rudikoff
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

2.  Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.

Authors:  G Lattanzio; C Libert; M Aquilina; M Cappelletti; G Ciliberto; P Musiani; V Poli
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

3.  Genetic mapping of tumor susceptibility genes involved in mouse plasmacytomagenesis.

Authors:  B A Mock; M M Krall; J K Dosik
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

4.  IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice.

Authors:  Donna L Thibault; Alvina D Chu; Kareem L Graham; Imelda Balboni; Lowen Y Lee; Cassidy Kohlmoos; Angela Landrigan; John P Higgins; Robert Tibshirani; Paul J Utz
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

5.  Multiple genetic loci modify susceptibility to plasmacytoma-related morbidity in E(mu)-v-abl transgenic mice.

Authors:  R C Andrew Symons; Mark J Daly; Jane Fridlyand; Terence P Speed; Wendy D Cook; Steven Gerondakis; Alan W Harris; Simon J Foote
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-30       Impact factor: 11.205

6.  Rapid induction of IgM-secreting murine plasmacytomas by pristane and an immunoglobulin heavy-chain promoter/enhancer-driven c-myc/v-Ha-ras retrovirus.

Authors:  R Clynes; J Wax; L W Stanton; S Smith-Gill; M Potter; K B Marcu
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

7.  Detection of recombinations between c-myc and immunoglobulin switch alpha in murine plasma cell tumors and preneoplastic lesions by polymerase chain reaction.

Authors:  S Janz; J Müller; J Shaughnessy; M Potter
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

8.  Mndal, a new interferon-inducible family member, is highly polymorphic, suppresses cell growth, and may modify plasmacytoma susceptibility.

Authors:  Ke Zhang; Daniel Kagan; Wendy DuBois; Richard Robinson; Valery Bliskovsky; William C Vass; Shuling Zhang; Beverly A Mock
Journal:  Blood       Date:  2009-08-04       Impact factor: 22.113

9.  T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors.

Authors:  D M Hilbert; M Y Shen; U R Rapp; S Rudikoff
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

10.  The tumor promoter pristane activates transcription by a cAMP dependent mechanism.

Authors:  S H Lee; C E Ackland-Berglund; C J Jones
Journal:  Mol Cell Biochem       Date:  1992-03-04       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.